BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38346605)

  • 1. Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer.
    Samia S; Sandeep Chary P; Khan O; Kumar Mehra N
    Int J Pharm; 2024 Mar; 653():123889. PubMed ID: 38346605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7.
    Leung LK; Wang TT
    Breast Cancer Res Treat; 1999 May; 55(1):73-83. PubMed ID: 10472781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy.
    Gibson LF; Fortney J; Magro G; Ericson SG; Lynch JP; Landreth KS
    Breast Cancer Res Treat; 1999 May; 55(2):107-17. PubMed ID: 10481938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro.
    Suzuki K; Kazui T; Yoshida M; Uno T; Kobayashi T; Kimura T; Yoshida T; Sugimura H
    Jpn J Clin Oncol; 1999 Jul; 29(7):323-31. PubMed ID: 10470656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of apoptosis regulators in breast cancer.
    Krajewski S; Krajewska M; Turner BC; Pratt C; Howard B; Zapata JM; Frenkel V; Robertson S; Ionov Y; Yamamoto H; Perucho M; Takayama S; Reed JC
    Endocr Relat Cancer; 1999 Mar; 6(1):29-40. PubMed ID: 10732784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation.
    Schmitt E; Sané AT; Steyaert A; Cimoli G; Bertrand R
    Biochem Cell Biol; 1997; 75(4):301-14. PubMed ID: 9493953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell lymphoma-2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy.
    Gong Q; Wang H; Zhou M; Zhou L; Wang R; Li Y
    Med Res Rev; 2024 Mar; 44(2):707-737. PubMed ID: 37983840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
    Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
    Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues.
    Yao Q; Chen J; Lv Y; Wang T; Zhang J; Fan J; Wang L
    Tumour Biol; 2011 Dec; 32(6):1163-71. PubMed ID: 21861179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
    Ogretmen B; Safa AR
    Int J Cancer; 1996 Sep; 67(5):608-14. PubMed ID: 8782646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
    Miller AV; Hicks MA; Nakajima W; Richardson AC; Windle JJ; Harada H
    PLoS One; 2013; 8(4):e60685. PubMed ID: 23577147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin A3 is associated with a poor prognosis in breast cancer and participates in the modulation of apoptosis in vitro by affecting the Bcl-2/Bax balance.
    Zeng C; Ke Z; Song Y; Yao Y; Hu X; Zhang M; Li H; Yin J
    Exp Mol Pathol; 2013 Aug; 95(1):23-31. PubMed ID: 23631820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNAi-peptide nanohybrid smart particles target BCL-2 oncogene and induce apoptosis in breast cancer cells.
    Alipour M; Sheikhnejad R; Fouani MH; Bardania H; Hosseinkhani S
    Biomed Pharmacother; 2023 Oct; 166():115299. PubMed ID: 37573657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer.
    Kandhavelu J; Subramanian K; Naidoo V; Sebastianelli G; Doan P; Konda Mani S; Yapislar H; Haciosmanoglu E; Arslan L; Ozer S; Thiyagarajan R; Candeias NR; Penny C; Kandhavelu M; Murugesan A
    Br J Pharmacol; 2024 Jan; 181(1):107-124. PubMed ID: 37183661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
    Wall NR; Mohammad RM; Al-Katib AM
    Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
    Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
    Merino D; Lok SW; Visvader JE; Lindeman GJ
    Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A strategy using mesoporous polymer nanospheres as nanocarriers of Bcl-2 siRNA towards breast cancer therapy.
    Wu X; Zheng Y; Yang D; Chen T; Feng B; Weng J; Wang J; Zhang K; Zhang X
    J Mater Chem B; 2019 Jan; 7(3):477-487. PubMed ID: 32254735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.